EpiPen Manufacturer Will Be A No-Show At Senate Hearing

FILE - In this July 8, 2016, file photo, a pharmacist holds a package of EpiPen epinephrine auto-injectors, a Mylan product, in Sacramento, Calif. On Wednesday, Nov. 9, 2016, Mylan Inc. reported company earnings. (AP... FILE - In this July 8, 2016, file photo, a pharmacist holds a package of EpiPen epinephrine auto-injectors, a Mylan product, in Sacramento, Calif. On Wednesday, Nov. 9, 2016, Mylan Inc. reported company earnings. (AP Photo/Rich Pedroncelli, File) MORE LESS

WASHINGTON (AP) — Senate Judiciary Chairman Charles Grassley says pharmaceutical company Mylan is declining to testify at his committee’s hearing next week on a settlement between the company and the Justice Department over its life-saving Epi-Pen.

Grassley on Monday released a letter from an attorney for Mylan saying officials would not testify. The Nov. 18 letter said company executives wouldn’t testify because the settlement is a pending matter and the Justice Department would also not be attending.

Mylan will pay $465 million to settle allegations that it overbilled Medicaid for EpiPen. At issue was whether the product should have been classified as generic under a Medicaid program.

The list price of EpiPens had grown to $608 for a two-pack, an increase of more than 500 percent since 2007.

Copyright 2016 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

2
Show Comments

Notable Replies

  1. Mylan to U.S.: “Pay up or die”

Continue the discussion at forums.talkingpointsmemo.com

Participants

Avatar for system1 Avatar for canyoncountry

Continue Discussion